Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 229.78M P/E - EPS this Y -2.40% Ern Qtrly Grth -
Income -211.6M Forward P/E -1.54 EPS next Y 59.20% 50D Avg Chg -48.00%
Sales 1.24M PEG 0.00 EPS past 5Y - 200D Avg Chg -61.00%
Dividend N/A Price/Book 4.33 EPS next 5Y 294.10% 52W High Chg -77.00%
Recommedations 2.40 Quick Ratio 2.30 Shares Outstanding 30.38M 52W Low Chg 34.00%
Insider Own 29.78% ROA -72.64% Shares Float 20.73M Beta 0.49
Inst Own 31.23% ROE -489.95% Shares Shorted/Prior 2.46M/2.97M Price 7.88
Gross Margin 55.31% Profit Margin - Avg. Volume 2,705,837 Target Price 13.25
Oper. Margin -12,942.52% Earnings Date Mar 7 Volume 1,419,617 Change 5.07%
About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BioXcel Therapeutics, Inc. News
02/22/24 15 Hot Penny Stocks On the Move
02/13/24 BioXcel Therapeutics Announces Termination of Proposed Public Offering
02/12/24 BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
02/08/24 BioXcel Therapeutics Announces Proposed Public Offering
02/06/24 BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
02/05/24 BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
12/12/23 BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
12/11/23 BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
11/30/23 BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
11/24/23 7 Penny Stocks With Low Floats and High Short Interest
11/16/23 BTAI: Alignment with FDA on At-Home Study of BXCL501 in Alzheimer’s Agitation…
11/16/23 BioXcel Therapeutics Third Quarter 2023 Earnings: Misses Expectations
11/15/23 BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript
11/15/23 Q3 2023 BioXcel Therapeutics Inc Earnings Call
11/14/23 BioXcel Therapeutics Inc (BTAI) Reports Q3 2023 Financial Results and Strategic Updates
11/14/23 BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
11/08/23 BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype
11/06/23 BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)
11/05/23 Following a 60% decline over last year, recent gains may please BioXcel Therapeutics, Inc. (NASDAQ:BTAI) institutional owners
10/31/23 BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023
BTAI Chatroom

User Image StockTradingMorty Posted - 1 hour ago

$BTAI 4$ today ? 😁

User Image Evissamwohs Posted - 6 hours ago

$BTAI

User Image Evissamwohs Posted - 1 day ago

$BTAI We all hope so

User Image PBbull Posted - 1 day ago

$BTAI double digits soon

User Image CODMIKE Posted - 2 days ago

$OCGN $BTAI $ADAP $ONMD Retailers insulting and getting mad at other retailers on this platform for making smart decisions for themselves whether their bulls/bears is beyond pathetic and a great example of how incompetent some of you truly are. Take your frustrations out on FIs and PEs lol they’re the ones laughing at you.

User Image Corpser1839 Posted - 2 days ago

$BTAI 4$ Next week? 🤔

User Image quietaccumulation Posted - 2 days ago

$BTAI SHORTY and pretend longs --see below ---wants it under 3.00 for the weekend

User Image CODMIKE Posted - 2 days ago

$BTAI Investor sentiment has definitely declined and with good reason. When a company pulls a stunt like BioXcel did last week it gives a sense of instability. Not to mention the shareholder lawsuits that are piling up. Although I’m happy with the turnout (termination of public offering) and expect more good news I’m glad I sold 50% of my position at 3.50 after catching it at the dip. I wouldn’t be surprised if the roller coaster isn’t over yet.

User Image Stokedemarket Posted - 2 days ago

$BTAI just got a few more shares!

User Image Ksmith614 Posted - 2 days ago

$BTAI what a joke! smdh

User Image Evissamwohs Posted - 2 days ago

$BTAI We are bound to have a small selloff before the weekend. A large portion of shorts and scalpers showing their presence.

User Image Cologne76 Posted - 2 days ago

$BTAI i hope Management will drop a update with good news for us

User Image Cologne76 Posted - 2 days ago

$BTAI bears you cant drop it go home and make a nap we will fly to to the roof without you

User Image quietaccumulation Posted - 2 days ago

$BTAI is that you 43% man buying scrambling to reload --cause we didnt sell

User Image ollerkeim Posted - 2 days ago

$BTAI to the 4$ moon!!!

User Image hahaaa Posted - 2 days ago

$BTAI super

User Image Evissamwohs Posted - 2 days ago

$BTAI

User Image shoagh12 Posted - 2 days ago

$BTAI we will see 4$ very soon...

User Image EveryGoodNameWasTaken Posted - 3 days ago

$BTAI used to be at 4 before the options game. Thanks for that, any idiot knew this would happen!

User Image Moneymode2021 Posted - 3 days ago

$BTAI drama maker turn into Trash maker. Let’s see what we gonna see!!

User Image Maineusa1 Posted - 3 days ago

$BTAI Nasdaq up over 500 , Btai will close at best up 5 cents but prob flat or down 😂😂

User Image Evissamwohs Posted - 3 days ago

$BTAI Shorts are cutting us down again leading up to market close.

User Image Evissamwohs Posted - 3 days ago

$BTAI

User Image Corpser1839 Posted - 3 days ago

$EBS $BTAI

User Image quietaccumulation Posted - 3 days ago

$BTAI look at her crawl back nice and steady --the way i like it ---hope 43% man got his fill

User Image crush7789 Posted - 3 days ago

$BTAI thoughts on funding options?

User Image Azhrarn Posted - 3 days ago

$BTAI Slow movements for BTAI today in a strong market. However the past days RSI has cooled down getting ready for a strong move up when volume hits. Limited risk with a sturdy $3 dollar resistance. Sooner or later company needs to come out with a solution to the cash problem, which might be the catalyst we need. Buckle up

User Image Berkshireannhathaway Posted - 3 days ago

$BTAI cmon 4$!

User Image shoagh12 Posted - 3 days ago

$BTAI 4$ easily ..

User Image quietaccumulation Posted - 3 days ago

$BTAI wonder how much 43% man lost trying to bring it down for his pals yesterday --failed

Analyst Ratings
UBS Neutral Feb 21, 24
HC Wainwright & Co. Buy Nov 15, 23
HC Wainwright & Co. Buy Oct 31, 23
HC Wainwright & Co. Buy Oct 26, 23
Truist Securities Hold Oct 5, 23
HC Wainwright & Co. Buy Sep 13, 23
HC Wainwright & Co. Buy Sep 8, 23
HC Wainwright & Co. Buy Aug 28, 23
Mizuho Neutral Aug 23, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Mehta Vimal CEO and President CEO and President Jun 14 Sell 21.22 60,000 1,273,200 39,903 06/16/23
Mehta Vimal CEO and President CEO and President Jun 14 Option 0.41 60,000 24,600 69,903 06/16/23
Steinhart Richard I Chief Financial Offi.. Chief Financial Officer May 14 Sell 27.17 5,000 135,850 1,500 05/16/23
Rodriguez Javier See Remarks See Remarks May 14 Sell 27.32 1,785 48,766 4,350 05/16/23
Nandabalan Krishnan Director Director Apr 06 Sell 17.32 60,000 1,039,200 04/10/23
Nandabalan Krishnan Director Director Apr 06 Option 0.41 60,000 24,600 60,000 04/10/23
Mehta Vimal CEO and President CEO and President Mar 20 Sell 19 64,500 1,225,500 15,894 03/22/23
Mehta Vimal CEO and President CEO and President Mar 20 Option 0.41 60,000 24,600 45,894 03/22/23
Yocca Frank Chief Scientific Off.. Chief Scientific Officer Jan 20 Sell 30.00 50,000 1,500,000 8,397 01/24/23
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Jan 20 Sell 30 29,713 891,390 01/24/23
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Jan 20 Option 0.41 29,713 12,182 29,713 01/24/23
Nandabalan Krishnan Director Director Jan 04 Sell 22.26 60,000 1,335,600 01/06/23
Nandabalan Krishnan Director Director Jan 04 Option 0.41 60,000 24,600 25,889 01/06/23
Mehta Vimal CEO and President CEO and President Dec 15 Option 0.41 60,000 24,600 39,957 12/19/22
Mehta Vimal CEO and President CEO and President Dec 15 Sell 19.8 60,000 1,188,000 9,957 12/19/22
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Feb 19 Option 5.71 25,000 142,750 25,000 02/19/21
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Feb 19 Sell 55.51 25,000 1,387,750 02/19/21
Yocca Frank Chief Scientific Off.. Chief Scientific Officer Jan 27 Option 0.41 15,000 6,150 103,397 01/27/21